Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

143.88 +0.30 (+0.21%)
Streaming Delayed Price Updated: 12:09 PM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
54 55 Next >
News headline image
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review ↗
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. 
Via Investor's Business Daily
Topics ETFs
News headline image
Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition ↗
Novartis AG (NYSE: NVS) has decided to step back from pursuing the Cytokinetics Inc (NASDAQ: CYTK) acquisition, dealing a blow to the potential deal with the  
Via Benzinga
News headline image
Bullish Continuation In '24? 3 Market Areas To Watch ↗
This article discusses 3 market areas that should outperform dramatically over the next 12 months... 
Via Talk Markets
News headline image
(NVS) - Analyzing Novartis's Short Interest ↗
 
Via Benzinga
Novartis AG (NYSE: NVS) Records 52-Week High Friday Morning
Via Investor Brand Network
News headline image
Big Players' Recent Trades in NVS Options ↗
 
Via Benzinga
News headline image
(NVS) - Analyzing Novartis's Short Interest ↗
 
Via Benzinga
News headline image
What's Been Happening With Cytokinetics Stock? ↗
Cytokinetics, Incorporated (NASDAQ: CYTK) shares are trading lower on Tuesday, pulling back from Monday strength. 
Via Benzinga
News headline image
Why Is Heart Failure Drug-Focused Cytokinetic Stock Trading Higher Today? ↗
Cytokinetics Inc (NASDAQ: CYTK) shares are trading higher after a report on potential takeover talks with Novartis AG (NYSE: NVS). 
Via Benzinga
News headline image
Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout Deal ↗
The company is working on a treatment for a disease that can lead to heart failure. 
Via Investor's Business Daily
News headline image
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today? ↗
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an  
Via Benzinga
Insufficient self-sufficiency of raw materials in Japan
Via AB Newswire
Topics Supply Chain
News headline image
Voyager Therapeutics stock pops 30% on deal with Novartis
Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took 
Via MarketBeat
News headline image
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value ↗
The year's biggest medical conference kicked off with a melee of buyout news. 
Via Investor's Business Daily
News headline image
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
News headline image
Google's AI Spin-Off Isomorphic Labs Strikes Big Pharma Deals, Paving the Way for Future of Drug Discovery ↗
Isomorphic Labs, a London-based spin-out of Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Google's AI R&D division DeepMind, has announced strategic part 
Via Benzinga
Topics Artificial Intelligence
News headline image
Alphabet's Isomorphic Labs In Drug Discovery Deals With Eli Lilly, Novartis ↗
Isomorphic Labs will get upfront cash and milestone payments. 
Via Investor's Business Daily
News headline image
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion ↗
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)... 
Via Talk Markets
News headline image
Voyager Therapeutics Stock Tanked After-Hours - Here's Why ↗
Voyager Therapeutics, Inc. (NASDAQ: VYGR) shares are trading lower in Thursday's after-hours session after announcing a proposed public offering  
Via Benzinga
News headline image
VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today ↗
VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration. 
Via InvestorPlace
News headline image
Why Is Gene Therapy Focused Voyager Therapeutics Stock Soaring Today? ↗
Voyager Therapeutics Inc (NASDAQ: VYGR) announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS), to advance pot 
Via Benzinga
News headline image
Novartis Sweetens Its Deal With Voyager, And Voyager Stock — Up 25% — Flashes A Bullish Sign ↗
The company inked an expanded collaboration deal with Novartis to test out gene therapies. 
Via Investor's Business Daily
News headline image
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
News headline image
Why Is Neurology Focused Cingulate Stock Trading Higher Today? ↗
On Tuesday, Cingulate Inc (NASDAQ: CING) received FDA guidance f 
Via Benzinga
News headline image
Why Is Cytokinetics (CYTK) Stock Up 70% Today? ↗
With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest. 
Via InvestorPlace
News headline image
Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals ↗
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of < 
Via Benzinga
News headline image
These 3 Big Pharma Stocks Are Making Big Plays With AI ↗
Opportunity is in the air with AI, and these pharma giants are seizing the moment. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug ↗
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... 
Via Benzinga
News headline image
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside ↗
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis... 
Via Benzinga
News headline image
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug ↗
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.